Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

Journal of the National Cancer Institute

Volumn 91, Issue 3, 1999, Pages 244-251

  Scher, Howard I ^a,b   Kelly, W M Kevin ^a   Zhang, Zuo Feng ^b   Ouyang, Peter ^c   Sun, Min ^b   Schwartz, Morton ^b   Ding, Cliff ^c   Wang, Weiping ^c   Horak, Ivan D ^c   Kremer, Alton B ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; EDATREXATE; ISOTRETINOIN; LACTATE DEHYDROGENASE; LIAROZOLE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID; SURAMIN; TUMOR MARKER;

AGE; AGED; ARTICLE; CANCER SURVIVAL; DISEASE MARKER; DRUG EFFICACY; HEMOGLOBIN DETERMINATION; HIGH RISK POPULATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SURVIVAL TIME; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0033518584     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.3.244     Document Type: Article

References (45)

1. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1899-903.
2. Schellhammer PF, Wright GL Jr. Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers. Urol Clin North Am 1993;20:597-606.
3. Scher HI. Prostate cancer: are we closer to rational treatment selection? Curr Opin Oncol 1992;4:442-54.
4. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer. J Clin Oncol 1993;11:607-15.
5. Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point in hormone refractory prostatic cancer. J Urol 1992;147:931-4.
6. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992;10:1754-61.
7. Amato RJ, Ellerhurst J, Bui C, Logothetis CJ. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol Oncol 1995;1:168-72.
8. Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994;12:2005-12.
9. Hudes GR, Nathan FE, Khater C, Greenberg R, Gomella L, Stern C, et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol 1995;22(5 Suppl 12):41-5.
10. Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer [published erratum appears in J Natl Cancer Inst 1994;86:463]. J Natl Cancer Inst 1994;86:222-7.
11. Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer [published erratum appears in J Natl Cancer Inst 1994;86:463]. J Natl Cancer Inst 1994;86:222-7.
12. Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 1995;13:2944-53.
13. Kelly WK, Scher HI, Mazumdar M, Pfister D, Curley T, Leibertz C, et al. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer. J Clin Oncol 1995;13:2214-22.
14. Dimopoulos MA, Panopoulos C, Bamia C, Deliveliotis C, Alivizatos G, Pantazopoulos D, et al. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 1997;50:754-8.
15. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998;16:1835-43.
16. Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M, Scher HI. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995;13:2208-13.
17. Stearns ME, Wang M, Fudge K. Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity [published erratum appears in Cancer Res 1993; 53:5831]. Cancer Res 1993;53:3073-7.
18. Stearns ME, Wang M, Fudge K. Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity [published erratum appears in Cancer Res 1993; 53:5831]. Cancer Res 1993;53:3073-7.
19. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35: 1-39.
20. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-9.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
22. Anonymous. SAS/STAT user guide. 6th ed. Cary (NC): SAS Institute Inc.; 1990.
23. Cox DR. Regression models and life table (with discussion). JR Stat Soc 1972;B34:187-220.
24. Cox DR. Partial likelihood. Biometrika 1975;62:269-79.
25. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996, by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-77.
26. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40.
27. Bander NH. Current status of monoclonal antibodies for imaging and therapy of prostate cancer. Semin Oncol 1994;21:607-12.
28. Kobayashi K, Vokes EE, Ratain MJ, Janisch L, Vogelzang NJ. Survival of prostate cancer patients treated with suramin by intermittent infusion without adaptive control: possible impact of prior flutamide therapy on survival [abstract]. Proc ASCO 1996;15:481.
29. Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LW. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 1996;88:794-801.
30. Eisenberger MA, Nelson WG. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! [editorial]. J Natl Cancer Inst 1996;88:779-81.
31. Eisenberger MA, Crawford ED, McLeod D, et al. A comparison of bilateral orchiectomy with or without flutamide in stage D2 prostate cancer. (NCI INT-0105 SWOG/ECOG). Proc ASCO 1997;16:3.
32. Young CY, Montgomery BT, Andrews PE, Qui SD, Bilhartz DL, Tindall DJ. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 1991;51: 3748-52.
33. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 1991;5:1921-30.
34. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, et al. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 1992;21:63-73.
35. Wolf DA, Schulz P, Fittler F. Transcription regulation of prostate kallikrein-like genes by androgen. Mol Endocrinol 1992;6:753-62.
36. Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst 1996;88:1623-34.
37. Leo ME, Bilhartz DL, Bergstrath EJ, Oesterling JE. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol 1991;145:802-6.
38. Gormley GJ, Stoner E, Brushkewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327: 1185-91.
39. Andrews PE, Young CY, Montgomery BT, Tindall DJ. Tumor-promoting phorbol ester down-regulates the androgen induction of prostate-specific antigen in a human prostatic adenocarcinoma cell line. Cancer Res 1992; 52:1525-9.
40. Peehl DM, Wong ST, Stamey TA. Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate 1993;23:69-78.
41. Dahiya R, Park HD, Cusick J, Vessella RL, Narayan P. Downregulation of PSA and tumorigenic potential by retinoic acid in prostate cancer cells [abstract]. Proc Am Assoc Cancer Res 1993;34:abstract 1751.
42. Samid D, Shack S, Myers CE. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 1993;91:2288-95.
43. Melchior S, Stone B, Santucci R, Brown L, True L, Daniel J, et al. Differentiation induces phenylacetate and phenylbutyrate and their effects in vitro and on the advanced prostate cancer (CaP) xenograft model LUCaP 23.1 [abstract]. Proc Am Assoc Cancer Res 1996;36:abstract 498.
44. Hsieh T, Chen SS, Wang X, Wu JM. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cell by ethanolic extracts of the Chinese herbal preparation. PC-SPES. Biochem Mol Biol 1997;42:535-44.
45. Palad AJ, Somers KD, Blackmore PF, Kohn EC, Rhim JS, Wright GL, et al. Sensitivities of human prostate tumor cell lines to the calcium influx inhibitor carboxyamidotriazole (CAI) [abstract]. Proc Am Assoc Cancer Res 1996;36:abstract 1669.